Filtered By:
Condition: Cholesterol
Education: Study
Countries: USA Health
This page shows you your search results in order of date.
Order by Relevance | Date
Total 136 results found since Jan 2013.
Can ‘toxic’ bilirubin treat a variety of illnesses?
Generations of medical and biology students have been instilled with a dim view of bilirubin. Spawned when the body trashes old red blood cells, the molecule is harmful refuse and a sign of illness. High blood levels cause jaundice, which turns the eyes and skin yellow and can signal liver trouble. Newborns can’t process the compound, and although high levels normally subside, a persistent surplus can cause brain damage.
Yet later this year up to 40 healthy Australian volunteers may begin receiving infusions of the supposedly good-for-nothing molecule. They will be participating in a phase 1 safety trial, sponsored ...
Source: ScienceNOW - June 8, 2023 Category: Science Source Type: news
Plain language summary of results from ORION-10 and ORION-11: Two studies to learn how well inclisiran works in people with high cholesterol
Future Cardiol. 2023 Jun 6. doi: 10.2217/fca-2022-0133. Online ahead of print.ABSTRACTWHAT IS THIS PLAIN LANGUAGE SUMMARY ABOUT?: This is a summary of the article describing the results of the ORION-10 and ORION-11 studies, which was published in the New England Journal of Medicine in April 2020. The studies included adult participants with atherosclerotic cardiovascular disease (ASCVD). ASCVD happens when the blood vessels that carry blood from the heart to other areas of the body are blocked by fatty build-up (plaque) causing a heart attack, stroke, or other problems. High levels of low-density lipoprotein cholesterol (L...
Source: Atherosclerosis - June 7, 2023 Category: Cardiology Authors: Kausik K Ray R Scott Wright Source Type: research
Prevalence and risk factors of retinal vein occlusion in the United States: The National Health and Nutrition Examination Survey, 2005 to 2008
Proc (Bayl Univ Med Cent). 2023 Feb 14;36(3):335-340. doi: 10.1080/08998280.2023.2173938. eCollection 2023.ABSTRACTRetinal vein occlusion (RVO) is a rare, vision-threatening vascular disorder. Due to limited recovery associated with RVO, prevention is essential. There is a significant discrepancy in previously reported epidemiological studies in the United States on the prevalence and risk factors of RVO. The purpose of this retrospective, cross-sectional study was to determine the prevalence and risk factors of RVO in adults ≥40 years of age in the US using the National Health and Nutrition Examination Survey (NHANES) 2...
Source: Baylor University Medical Center Proceedings - April 24, 2023 Category: Universities & Medical Training Authors: Praneeth Kalva Rubeel Akram Hafsa Z Zuberi Karanjit S Kooner Source Type: research
Stroke Mortality Among Black and White Adults Aged ≥35 Years Before and During the COVID-19 Pandemic - United States, 2015-2021
MMWR Morb Mortal Wkly Rep. 2023 Apr 21;72(16):431-436. doi: 10.15585/mmwr.mm7216a4.ABSTRACTStroke is the fifth leading cause of death and a leading cause of long-term disability in the United States (1). Although stroke death rates have declined since the 1950s, age-adjusted rates remained higher among non-Hispanic Black or African American (Black) adults than among non-Hispanic White (White) adults (1,2). Despite intervention efforts to reduce racial disparities in stroke prevention and treatment through reducing stroke risk factors, increasing awareness of stroke symptoms, and improving access to treatment and care for s...
Source: MMWR Morb Mortal Wkl... - April 21, 2023 Category: Epidemiology Authors: Quanhe Yang Xin Tong Linda Schieb F átima Coronado Robert Merritt Source Type: research
Straight from the heart: Mysterious lipids may predict cardiac problems better than cholesterol
Stephanie Blendermann, 65, had good reason to worry about heart disease. Three of her sisters died in their 40s or early 50s from heart attacks, and her father needed surgery to bypass clogged arteries. She also suffered from an autoimmune disorder that results in chronic inflammation and boosts the odds of developing cardiovascular illnesses. “I have an interesting medical chart,” says Blendermann, a real estate agent in Prior Lake, Minnesota.
Yet Blendermann’s routine lab results weren’t alarming. At checkups, her low-density lipoprotein (LDL), or “bad,” cholesterol hovered around the 100 milligrams-per-...
Source: Science of Aging Knowledge Environment - March 16, 2023 Category: Geriatrics Source Type: research
' Bad ' cholesterol, high blood pressure combo may heighten risk of heart attack, stroke
A combination of ' bad ' cholesterol and high blood pressure may increase a person ' s risk of heart attack or stroke, a long-term study of several thousand men and women in the United States suggests.
Source: Health News - UPI.com - December 13, 2022 Category: Consumer Health News Source Type: news
What to Know About Diabetes and the Risk of Silent Heart Attacks
At first it seemed like a routine call—something the paramedics had dealt with countless times before. A man in his mid-50s was having a heart attack, and his physician had called for emergency support. But when the paramedics arrived, the physician pulled them aside and told them something peculiar: the man had no cardiovascular symptoms whatsoever.
The man had come to his doctor’s office because he’d woken early the previous morning sweating and with a sharp pain in his left wrist. These symptoms had quickly subsided and he’d gone back to sleep. Later, after going about his day, he’d visited...
Source: TIME: Health - November 4, 2022 Category: Consumer Health News Authors: Markham Heid Tags: Uncategorized healthscienceclimate heart health Source Type: news
Long-Term Evolocumab in Patients with Established Atherosclerotic Cardiovascular Disease
CONCLUSIONS: Long-term LDL-C lowering with evolocumab was associated with persistently low rates of adverse events for over >8 years that did not exceed those observed in the original placebo arm during the parent study and led to further reductions in cardiovascular events compared with delayed treatment initiation.PMID:36031810 | DOI:10.1161/CIRCULATIONAHA.122.061620
Source: Circulation - August 29, 2022 Category: Cardiology Authors: Michelle L O'Donoghue Robert P Giugliano Stephen D Wiviott Dan Atar Anthony C Keech Julia F Kuder KyungAh Im Sabina A Murphy Jose H Flores-Arredondo J Antonio G Lopez Mary Elliott-Davey Bei Wang Maria Laura Monsalvo Siddique Abbasi Marc S Sabatine Source Type: research
LDL-C target attainment in secondary prevention of ASCVD in the United States: barriers, consequences of nonachievement, and strategies to reach goals
Postgrad Med. 2022 Aug 25. doi: 10.1080/00325481.2022.2117498. Online ahead of print.ABSTRACTAtherosclerotic cardiovascular disease (ASCVD) is the leading cause of death in the United States. Elevated low-density lipoprotein cholesterol (LDL-C) is a major causal risk factor for ASCVD. Current evidence overwhelmingly demonstrates that lowering LDL-C reduces the risk of secondary cardiovascular events in patients with previous myocardial infarction or stroke. There is no lower limit for LDL-C: large, randomized studies and meta-analyses have found continuous benefit and no safety concerns in patients achieving LDL-C levels &...
Source: Postgraduate Medicine - August 25, 2022 Category: Internal Medicine Authors: James Underberg Peter P Toth Fatima Rodriguez Source Type: research
